CN105073751B - 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑 - Google Patents

作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑 Download PDF

Info

Publication number
CN105073751B
CN105073751B CN201380073382.4A CN201380073382A CN105073751B CN 105073751 B CN105073751 B CN 105073751B CN 201380073382 A CN201380073382 A CN 201380073382A CN 105073751 B CN105073751 B CN 105073751B
Authority
CN
China
Prior art keywords
substituted
alkyl
compound
occurrence
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380073382.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073751A (zh
Inventor
U.韦拉帕蒂
C.P.达恩
D.S.多德
A.J.桑波纳罗
M.D.维特曼
S.库马拉维尔
D.马利克
R.C.雷迪
P.刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN105073751A publication Critical patent/CN105073751A/zh
Application granted granted Critical
Publication of CN105073751B publication Critical patent/CN105073751B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201380073382.4A 2012-12-21 2013-12-20 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑 Expired - Fee Related CN105073751B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740564P 2012-12-21 2012-12-21
US61/740564 2012-12-21
PCT/US2013/076795 WO2014100533A1 (en) 2012-12-21 2013-12-20 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS

Publications (2)

Publication Number Publication Date
CN105073751A CN105073751A (zh) 2015-11-18
CN105073751B true CN105073751B (zh) 2018-11-30

Family

ID=49943572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380073382.4A Expired - Fee Related CN105073751B (zh) 2012-12-21 2013-12-20 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑

Country Status (5)

Country Link
US (1) US9556179B2 (OSRAM)
EP (1) EP2935271B1 (OSRAM)
JP (1) JP6267231B2 (OSRAM)
CN (1) CN105073751B (OSRAM)
WO (1) WO2014100533A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
ES2770693T3 (es) * 2014-06-19 2020-07-02 Bristol Myers Squibb Co Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
US10696693B2 (en) 2014-11-21 2020-06-30 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as TGF-beta inhibitors
EP3265454B1 (en) * 2015-03-02 2020-02-26 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
JP6827948B2 (ja) 2015-03-23 2021-02-10 ザ ユニヴァーシティー オブ メルボルン 呼吸器疾患の治療
AU2016304182B2 (en) 2015-07-31 2020-08-27 Merck Patent Gmbh Bicyclic heterocyclic derivatives
CA3037222C (en) 2016-09-21 2024-02-13 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
EP3774795B1 (en) * 2018-03-29 2022-03-16 Masarykova Univerzita 4-(1h- imidazol- 5- yl) -1h-pyrrolo [2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
EP3846818A1 (en) * 2018-09-09 2021-07-14 Qanatpharma AG Use of casein kinase 1 inhibitors for treating vascular diseases
EP3877383A4 (en) 2018-11-07 2022-09-21 The University of Melbourne COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
US11739078B2 (en) * 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
KR20230153407A (ko) 2021-02-24 2023-11-06 인실리코 메디신 아이피 리미티드 질환의 치료를 위한 유사체
WO2025231117A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof
WO2025231112A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016131A1 (en) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8703811B2 (en) 2008-05-07 2014-04-22 Genzyme Corporation Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
HRP20140252T1 (hr) 2009-10-28 2014-04-25 Pfizer Inc. Derivati imidazola kao inhibitori kazeinske kinaze
EP2935272B1 (en) 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Also Published As

Publication number Publication date
EP2935271A1 (en) 2015-10-28
JP2016507502A (ja) 2016-03-10
US9556179B2 (en) 2017-01-31
WO2014100533A1 (en) 2014-06-26
CN105073751A (zh) 2015-11-18
EP2935271B1 (en) 2017-10-25
US20150344481A1 (en) 2015-12-03
JP6267231B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
CN105073751B (zh) 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
JP7076432B2 (ja) Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
CN109952303B (zh) Tyk2抑制剂及其用途
TWI748539B (zh) Cot調節劑及其使用方法
CN100549011C (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
CN114057771B (zh) 大环化合物及其制备方法和应用
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
US20250368641A1 (en) Quinoline compounds as inhibitors of kras
JP7631317B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としてのトリアゾロピリミジン
CN113454083A (zh) Kras突变蛋白抑制剂
JP2022024019A (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
JP2024529347A (ja) Ｋｒａｓの阻害剤としての三環式化合物
CN105745209B (zh) 三唑并吡啶化合物、组合物及其使用方法
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
TW201713641A (zh) 經取代之喹喏啉衍生物
EP4039688B1 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
WO2014053568A1 (en) Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
TW201321371A (zh) 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
CN108530464B (zh) 一种多靶点激酶抑制剂
JP7537002B2 (ja) Ｃｄｋ９阻害剤およびその使用
JP2020537661A (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
HK40065459A (en) Kras mutant protein inhibitors
HK40052926A (en) Kras mutant protein inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181130

Termination date: 20211220